Literature DB >> 1719797

How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation.

H Mohri1, T Ohkubo.   

Abstract

Vitronectin, which is present in both plasma and extracellular matrix, inhibits the complement cascade and promotes the growth and attachment of cells in vitro. Like other adhesive proteins such as fibrinogen, von Willebrand factor, and fibronectin, vitronectin contains the sequence Arg-Gly-Asp and binds to some members of the family of receptors called integrins. Platelet membrane glycoprotein IIb-IIIa (GPIIb-IIIa) is well known as a member of integrins that bind to vitronectin as well as to fibrinogen, von Willebrand factor, and fibronectin. The interaction of vitronectin with GPIIb-IIIa was studied. Vitronectin bound to thrombin-stimulated platelets in a calcium-dependent, specific, and saturable manner with a molecular weight of 290 nmol/L and 9,100 sites per platelet. The binding was inhibited by the other adhesive proteins with IC50s of 0.078-0.15 mumol/L. The binding also was inhibited by the tetrapeptide Arg-Gly-Asp-Ser and the monoclonal antibody to GPIIb-IIIa (LJ-CP8). Vitronectin inhibited thrombin-induced platelet aggregation in a dose-dependent manner and fibrinogen enhanced platelet aggregation. These results suggest that vitronectin might modulate platelet aggregates by interfering with the interaction of fibrinogen with thrombin-activated GPIIb-IIIa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719797     DOI: 10.1093/ajcp/96.5.605

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Serum vitronectin levels in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Aslıhan Uzun; F Nilüfer Yalçındağ; Namık Delibaş
Journal:  Inflamm Res       Date:  2012-07-19       Impact factor: 4.575

2.  Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1.

Authors:  B Titz; S Dietrich; T Sadowski; C Beck; A Petersen; R Sedlacek
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

3.  Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease.

Authors:  Hakan Ekmekci; Huseyin Sonmez; Ozlem B Ekmekci; Zeynep Ozturk; Nergiz Domanic; Emine Kokoglu
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

4.  Prognostic utility of serum vitronectin levels in acute myocardial infarction.

Authors:  S Aslan; B Ikitimur; H A Cakmak; B Karadag; E Y Tufekcioglu; H Ekmekci; H Yuksel
Journal:  Herz       Date:  2014-05-15       Impact factor: 1.443

5.  Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex.

Authors:  K Høgåsen; T E Mollnes; P Brandtzaeg
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  A deficiency of uPAR alters endothelial angiogenic function and cell morphology.

Authors:  Rashna D Balsara; Reid Merryman; Farhaad Virjee; Claire Northway; Francis J Castellino; Victoria A Ploplis
Journal:  Vasc Cell       Date:  2011-05-02

7.  Correlation of Serum Levels of Vitronectin, Malondialdehyde and Hs- CRP With Disease Severity in Coronary Artery Disease.

Authors:  Alireza Yaghoubi; Morteza Ghojazadeh; Sakhavat Abolhasani; Hossein Alikhah; Fatemeh Khaki-Khatibi
Journal:  J Cardiovasc Thorac Res       Date:  2015
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.